StockNews.AI
PTGX
StockNews.AI
13 days

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

1. Protagonist submitted NDA for icotrokinra for psoriasis, signaling strong product pipeline. 2. Company reports $673 million cash reserves, ensuring funding through late 2028.

Earnings
-5.42%Current Return
VS
-0.07%S&P 500
$53.8808/06 04:11 PM EDTEvent Start
$50.9608/07 11:08 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The NDA filing for icotrokinra represents significant potential in a lucrative market, similar to previous successful drug launches that enhanced stock valuations.

How important is it?

The NDA for icotrokinra directly impacts PTGX’s future revenue and market position, indicating strong corporate performance and growth prospects.

Why Long Term?

With projected cash reserves supporting developmental phases until 2028, PTGX is well-positioned for sustainable growth driven by forthcoming product approvals.

Related Companies

VRTXABBVREGN
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th Phase 3 VERIFY trial data set of rusfertide in polycythemia vera (PV) presented during plenary session at ASCO; U.S. NDA filing on track for Q4 Cash, cash equivalents and marketable securities of $673.0 million as of June 30, 2025, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / August 6, 2025 / Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. "Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist, as we saw rusfertide the topic of the prestigious ASCO Plenary Session in May, the announcement of an oral and injectable triple agonist anti-obesity peptide development candidate in June, and most recently the first ever NDA filing of icotrokinra for psoriasis last month," said Dinesh V.

Related News